ATE — Antibe Therapeutics(Pre-Merger) Share Price
0.000.00%
Last trade - 00:00- CA$15.64m
- -CA$9.27m
- 24
- 46
- 14
- 18
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 0.6 | ||
| Price to Tang. Book | n/a | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | n/a | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -37.16% | ||
| Return on Equity | -52.72% | ||
| Operating Margin | n/a | ||
Financial Summary
| Year End 31st Mar | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | CA$m | 9.54 | 9.67 | 9.71 | n/a | n/a | n/a | n/a | -100% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.
Directors
- Walter Macnee NEC (64)
- Daniel Legault PRE
- John Wallace FDR
- Alain Wilson CFO
- Scott Curtis EVP
- Joseph Stauffer OTH
- David Vaughan OTH
- Roderick Flower IND
- Robert Hoffman IND (57)
- Amal Khouri IND
- Jennifer McNealey IND (47)
- Yung Wu IND
- Last Annual
- March 31st, 2023
- Last Interim
- December 31st, 2023
- Incorporated
- May 5th, 2009
- Public Since
- January 1st, 1970
- No. of Employees
- 11
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- Toronto Stock Exchange
- Shares in Issue
- 53,009,362
- Address
- 15 Prince Arthur Avenue, TORONTO, M5R 1B2
- Web
- https://www.antibethera.com/
- Phone
- +1 9057260995
- Contact
- Christina Cameron
- Auditors
- Ernst & Young LLP
Upcoming Events for ATE
Similar to ATE
AEterna Zentaris
Toronto Stock Exchange
Appili Therapeutics
Toronto Stock Exchange
Aptose Biosciences
Toronto Stock Exchange
Avicanna
Toronto Stock Exchange
Briacell Therapeutics
Toronto Stock Exchange
FAQ
What is the Antibe Therapeutics(Pre-Merger) share price?
As of Today at 19:02 UTC, shares in Antibe Therapeutics(Pre-Merger) are trading at CA$0.30. This share price information is delayed by 15 minutes.
How has the Antibe Therapeutics(Pre-Merger) share price performed this year?
Shares in Antibe Therapeutics(Pre-Merger) last closed at CA$0.30 and the price had moved by -47.32% over the past 365 days. In terms of relative price strength the Antibe Therapeutics(Pre-Merger) share price has underperformed the Toronto Stock Exchange 300 Composite Index by -50.5% over the past year.
What are the analyst and broker recommendations for Antibe Therapeutics(Pre-Merger)?
The overall consensus recommendation for Antibe Therapeutics(Pre-Merger) is Hold. You can view the full broker recommendation list by unlocking its StockReport.
What is the Antibe Therapeutics(Pre-Merger) dividend yield?
Antibe Therapeutics(Pre-Merger) does not currently pay a dividend.
Does Antibe Therapeutics(Pre-Merger) pay a dividend?
Antibe Therapeutics(Pre-Merger) does not currently pay a dividend.
When does Antibe Therapeutics(Pre-Merger) next pay dividends?
Antibe Therapeutics(Pre-Merger) does not currently pay a dividend.
How do I buy Antibe Therapeutics(Pre-Merger) shares?
To buy shares in Antibe Therapeutics(Pre-Merger) you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Antibe Therapeutics(Pre-Merger)?
As of the previous close price of CA$0.30, shares in Antibe Therapeutics(Pre-Merger) had a market capitalisation of CA$15.64m.
Where are Antibe Therapeutics(Pre-Merger) shares listed?
Here are the trading details for Antibe Therapeutics(Pre-Merger):
- Country of listing: Canada
- Exchange: TOR
- Ticker Symbol: ATE
What kind of share is Antibe Therapeutics(Pre-Merger)?
Based on an overall assessment of its quality, value and momentum Antibe Therapeutics(Pre-Merger) is currently classified as a Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Antibe Therapeutics(Pre-Merger) share price forecast for 2024?
The analyst consensus target price for shares in Antibe Therapeutics(Pre-Merger) is CA$1.25. That is 323.73% above the last closing price of CA$0.30.
Analysts covering Antibe Therapeutics(Pre-Merger) currently have a consensus Earnings Per Share (EPS) forecast of -CA$0.33 for the next financial year.
What is the trend in the Antibe Therapeutics(Pre-Merger) share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Antibe Therapeutics(Pre-Merger). Over the past six months, its share price has underperformed the Toronto Stock Exchange 300 Composite Index by -44.36%.
As of the last closing price of CA$0.30, shares in Antibe Therapeutics(Pre-Merger) were trading -55.16% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Antibe Therapeutics(Pre-Merger) PE Ratio?
The Antibe Therapeutics(Pre-Merger) PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at CA$0.30.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Antibe Therapeutics(Pre-Merger)?
Antibe Therapeutics(Pre-Merger)'s management team is headed by:
- Walter Macnee - NEC
- Daniel Legault - PRE
- John Wallace - FDR
- Alain Wilson - CFO
- Scott Curtis - EVP
- Joseph Stauffer - OTH
- David Vaughan - OTH
- Roderick Flower - IND
- Robert Hoffman - IND
- Amal Khouri - IND
- Jennifer McNealey - IND
- Yung Wu - IND